Physician profile
Christopher M Gal
NPI 1467890012
$2,267.18
in general payments reported to CMS, 2019-2025
24 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.65 · 2021: $581 · 2022: $433 · 2023: $428 · 2024: $449 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $742.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.70 | 2020-2025 | Entyvio |
| Gilead Sciences, INC. | $142.84 | 2021-2023 | |
| Genzyme Corporation | $142.48 | 2025 | |
| Nestle Healthcare Nutrition INC. | $140.44 | 2020-2023 | |
| Boston Scientific Corporation | $125.31 | 2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $111.82 | 2020-2023 | Dificid |
| Janssen Biotech, INC. | $100.51 | 2021-2024 | Simponi Aria, Simponi, Tremfya |
| Intercept Pharmaceuticals, INC. | $79.70 | 2021-2023 | Ocaliva |
| Braintree Laboratories, INC. | $67.63 | 2023-2025 | Sutab, Suflave |
| Pentax of America, INC. | $64.07 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.36 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $58.89 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $46.59 | 2024-2025 | Sucraid, Sucraid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.25 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $30.92 | 2022-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $23.94 | 2023 | Dupixent |
| Ardelyx, INC. | $21.28 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $18.24 | 2025 | Voquezna |
| Olympus America INC. | $17.22 | 2023 | Endoclot Phs |
| Redhill Biopharma INC. | $16.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.37 | 2021 | |
| Pfizer INC. | $14.51 | 2025 | |
| Micro-Tech Endoscopy USA, INC. | $7.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.